ArticlebioRxiv : the preprint server for biology2023
Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants.
Abstract readPreprint
In one paragraph
Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Updated by
Authors and funding
43 authors.
Thomas A DesautelsComputational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Kathryn T ArrildtBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Adam T ZemlaGlobal Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Edmond Y LauBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Fangqiang ZhuBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Dante RicciBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Stephanie CroninVanderbilt Vaccine Center, Nashville, TN 37232, USA.
Seth J ZostVanderbilt Vaccine Center, Nashville, TN 37232, USA.
Elad BinshteinVanderbilt Vaccine Center, Nashville, TN 37232, USA.
Suzanne M ScheafferDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Bernadeta DadonaiteBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Brenden K PetersenComputational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Taylor B EngdahlVanderbilt Vaccine Center, Nashville, TN 37232, USA.
Elaine ChenVanderbilt Vaccine Center, Nashville, TN 37232, USA.
Laura S HandalVanderbilt Vaccine Center, Nashville, TN 37232, USA.
Lynn HallVanderbilt Vaccine Center, Nashville, TN 37232, USA.
John W GoforthGlobal Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Denis VashchenkoApplications Simulations and Quality Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Sam NguyenComputational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Dina R WeilhammerBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Jacky Kai-Yin LoBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Bonnee RubinfeldBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Edwin A SaadaBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Tracy WeisenbergerBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Tek-Hyung LeeBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Bradley WhitenerDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
James B CaseDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Alexander LaddComputational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Mary S SilvaGlobal Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Rebecca M HaluskaApplications Simulations and Quality Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Emilia A GrzesiakGlobal Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Christopher G EarnhartJoint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, US, Department of Defense, Frederick, MD 21703, USA.
Svetlana HopkinsJoint Research & Development, Inc., Stafford, VA 22556, USA.
Thomas W BatesGlobal Security Directorate, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Larissa B ThackrayDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Brent W SegelkeBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Antonietta Maria LilloLos Alamos National Laboratory, Bioscience Division, Los Alamos, NM 87545, USA.
Shivshankar SundaramCenter for Bioengineering, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Jesse BloomBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
James E CroweVanderbilt Vaccine Center, Nashville, TN 37232, USA.
Robert H CarnahanVanderbilt Vaccine Center, Nashville, TN 37232, USA.
Daniel M FaissolComputational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Funding
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MProspectively characterizing the functional and antigenic effects of mutations to viral entry proteinsR01AI141707 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2018 to 2022
$2.1MNIAID NIH HHS 75N93019C00051NIAID NIH HHS R01 AI141707NIAID NIH HHS R01 AI157155
Abstract
The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.